Sugi Predict

Sugi Predict / Compounds / Potassium

Potassium

Potassium

SCHEMBL1531376

COc1ccc([N+](=O)[O-])cc1O.[K]

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.62
▸ HTT P42858 3/20 0.59
▸ MEN1 O00255 4/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ RAB9A P51151 1/20 0.57
▸ TLR9 Q9NR96 1/20 0.57
▸ GPR35 Q9HC97 2/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ KCNMA1 Q12791 2/20 0.53
▸ PKM P14618 1/20 0.53
▸ CYP19A1 P11511 1/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ MAPT P10636 3/20 0.50
▸ TP53 P04637 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL29837395 0.98 TDP1 (0.60) TDP1HTTMEN1KMT2ARAB9A
SCHEMBL443353 0.98 TDP1 (0.64) TDP1HTTMEN1KMT2ARAB9A
SCHEMBL31375357 0.98 TDP1 (0.64) TDP1HTTMEN1KMT2ARAB9A
SCHEMBL3250030 0.96 TDP1 (0.62) TDP1HTTMEN1KMT2ARAB9A
SCHEMBL3250031 0.96 TDP1 (0.62) TDP1HTTMEN1KMT2ARAB9A
SCHEMBL237798 0.96 TDP1 (0.62) TDP1HTTMEN1KMT2ARAB9A
Ammonia Solution, Strong SCHEMBL28302338 0.96 TDP1 (0.62) TDP1HTTMEN1KMT2ARAB9A
SCHEMBL27906072 0.96 TDP1 (0.62) TDP1HTTMEN1KMT2ARAB9A
Hydrochloric Acid SCHEMBL28153337 0.95 TDP1 (0.60) TDP1HTTMEN1KMT2ARAB9A
Acetone SCHEMBL28118102 0.92 TDP1 (0.57) TDP1HTTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346872-B1 AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2015-11-25 — — EP disclosed
US-8754211-B2 Azolotriazinone melanin concentrating hormone receptor-1 antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2014-06-17 — — US disclosed
US-20140031337-A1 AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-30 — — US disclosed
US-8618115-B2 Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them BRISTOL-MYERS SQUIBB COMPANY (US) 2013-12-31 — — US disclosed
US-8580959-B2 Azolotriazinone melanin concentrating hormone receptor-1 antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-12 — — US disclosed
EP-1948665-B1 THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2013-02-27 — — EP disclosed
US-8344160-B2 Pyrrolone melanin concentrating hormone receptor-1 antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-01 — — US disclosed
EP-2346860-B1 PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2012-09-19 — — EP disclosed
US-20110218185-A1 AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS SYNGENE INTERNATIONAL LIMITED (IN) 2011-09-08 — — US disclosed
US-20110195986-A1 PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2011-08-11 — — US disclosed
WO-2007050723-A1 THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-03 — — WO disclosed
US-20070093509-A1 Non-basic melanin concentrating hormone receptor-1 antagonists BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 — — US disclosed
US-20060173034-A1 Novel 4-anilinoquinoline-3-carboxamides ASTRAZENECA AB (SE) 2006-08-03 — — US disclosed
US-7037925-B2 4-anilinoquinoline-3-carboxamides ASTRAZENECA AB (SE) 2006-05-02 — — US disclosed
US-20040248923-A1 Novel 4-anilinoquinoline-3-carboxamides ASTRAZENECA AB (SE) 2004-12-09 — — US disclosed
EP-1387830-A1 NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES AstraZeneca AB (SE) 2004-02-11 — — EP disclosed
WO-2002092571-A1 NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES ASTRAZENECA AB (SE) 2002-11-21 — — WO disclosed
EP-0603964-B1 Azopyrazolone masking couplers EASTMAN KODAK CO (US) 1999-03-10 — — EP disclosed
US-5492799-A Azopyrazolone masking couplers EASTMAN KODAK COMPANY (US) 1996-02-20 — — US disclosed
EP-0603964-A2 Azopyrazolone masking couplers EASTMAN KODAK COMPANY (US) 1994-06-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248923-A1 Novel 4-anilinoquinoline-3-carboxamides JAK3, JAK2, JAK1 TDP1 4594/4885HTT 4311/4885MEN1 3698/4885
US-20070093509-A1 Non-basic melanin concentrating hormone receptor-1 antagonists MCHR1, MCHR2, MC1R TDP1 2046/4885HTT 704/4885MEN1 512/4885
US-20110195986-A1 PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS MCHR1, MCHR2, MC1R TDP1 2301/4885HTT 705/4885MEN1 1576/4885
US-20060173034-A1 Novel 4-anilinoquinoline-3-carboxamides JAK3, JAK2, JAK1 TDP1 3868/4885HTT 3432/4885MEN1 3584/4885
US-20140031337-A1 AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS MCHR1, MCHR2, MC1R TDP1 3281/4885HTT 965/4885MEN1 551/4885
US-20110218185-A1 AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS MCHR1, MCHR2, MC1R TDP1 3281/4885HTT 965/4885MEN1 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.